Sökning: "antiidiotypic antibody"

Hittade 3 avhandlingar innehållade orden antiidiotypic antibody.

  1. 1. Strategies to improve cancer radioimmunotargeting

    Författare :Anders Ullén; Umeå universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; : cancer; monoclonal antibody; antiidiotypic antibody; radioimmunotargeting; placental alkaline phosphatase; cytokeratin; BIAcore.;

    Sammanfattning : Radioimmunotherapy (RIT) and radioimmunolocalisation (RIL) are developing and promising technologies to diagnose and treat tumours by use of radiolabelled antibodies targeting tumour specific antigens. The major reason why RIL and RIT not are efficient enough, is the comparatively low accumulation of radiolabelled antibodies in the tumours. LÄS MER

  3. 2. Interaction studies of idiotypic and antiidiotypic antibodies at experimental tumor targeting

    Författare :Ann Erlandsson; Mats Ohlin; Umeå universitet; []
    Nyckelord :anti-idiotypic antibody; clearing; cytokeratin 8; epitope; idiotypic antibody; immunotherapy;

    Sammanfattning : An increasing number of antibodies are being labeled with radionuclides for immunotargeting, but the negative side effects generated on normal tissues by the nuclide remains a significant problem. The clearing of non-tumor-targeted radiolabeled antibodies from the circulation contributes significantly to improved targeting; it has been demonstrated that anti-idiotypic antibodies can be used for this purpose. LÄS MER

  4. 3. Monoclonal antibodies and cytokines for therapy of patients with advanced colorectal carcinoma : a clinical and immunological study

    Författare :Anna-Lena Hjelm Skog; Karolinska Institutet; Karolinska Institutet; []
    Nyckelord :Colorectal carcinoma; Monoclonal antibodies; IL-2; IFN-[alpha]; GM-CSF; cytokine antibodies; neopterin; sIL-2R; immune suppression;

    Sammanfattning : There is a great need for developing and improving treatment alternatives in colorectal carcinoma (CRC). The tumour associated antigen (TAA) GA733/CO17-1A is expressed by more than 90% of all CRCs, on the majority of both primary and metastatic CRC cells. LÄS MER